
The Brinzei MDMA-PTSD Protocol: Addressing the Food and Drug Administration's Breaking Blind Concerns with Precision Approaches to Post-Traumatic Stress Disorder Treatment

[Octavian Victor Brinzei](#) *

Posted Date: 19 May 2026

doi: 10.20944/preprints202510.0252.v3

Keywords: MDMA-assisted therapy; PTSD treatment; psychedelic medicine; neurobiological mechanisms; breaking blind



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC, OpenAlex.

Copyright: This open access article is published under a [Creative Commons CC BY 4.0 license](#), which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Hypothesis

The Brinzei MDMA-PTSD Protocol: Addressing the Food and Drug Administration's Breaking Blind Concerns with Precision Approaches to Post-Traumatic Stress Disorder Treatment

Octavian Victor Brinzei ^{1,2}

¹ Psynergetic Sciences, Australia; publications@brinzeigroup.com.au

² Mind Medicine Australia, Australia

Key Points

1. Strong evidence shows MDMA-assisted therapy can produce large, lasting reductions in PTSD symptoms.
2. Blinding remains problematic because MDMA's psychoactive effects are obvious to participants.
3. TAML model explains how trauma memories are stored, reactivated, and reinforced in brain circuits.
4. MDMA creates a "therapeutic window" by lowering fear signals and enhancing emotional regulation.
5. Different trauma types respond differently: acute trauma may resolve quickly, while complex trauma needs extended care.
6. Introduction of BMPP, a new clinical trial design uses role-based masking to reduce bias while supporting effective therapy.

Plain Language Summary

Post-traumatic stress disorder (PTSD) is one of the hardest mental-health conditions to treat. Recent studies have shown that therapy using 3,4-methylenedioxymethamphetamine (MDMA) can produce large and lasting improvements for people with severe PTSD. However, the United States Food and Drug Administration (FDA) recently rejected an MDMA application, arguing that clinical trials were unblinded. Because MDMA causes clear psychoactive effects, participants and therapists often know who received the drug, making true placebo control impossible. This paper focuses on solving that problem. It introduces the Trauma-Affective Memory Loop (TAML), a simple model describing how traumatic memories are stored, re-triggered, and emotionally reinforced through brain areas such as the amygdala, hippocampus, and anterior cingulate cortex. MDMA appears to reduce fear signals in these circuits, creating a short-term therapeutic window in which patients can recall and re-process traumatic memories safely. Different trauma types may need different treatment approaches. Single-event trauma (for example, assault or accidents) may respond after one to three MDMA sessions, while complex or developmental trauma (from long-term abuse or neglect) may require multiple, carefully planned treatments integrated with psychotherapy. Finally, the paper presents the Brinzei MDMA-PTSD Protocol (BMPP), a next-generation clinical-trial design that uses role separation and quadruple masking to minimise bias while keeping therapy safe and effective. The goal is to move beyond debates about blinding and toward understanding how MDMA works, who benefits most, and how to deliver this treatment responsibly within modern regulatory standards.

Abstract

3,4-Methylenedioxyamphetamine (MDMA) has been shown in multiple clinical trials to greatly reduce Post-Traumatic Stress Disorder (PTSD) symptoms, with many patients experiencing lasting improvement. However, recent regulatory rejection based on problems with blinding highlights a

contradiction, with regulatory agencies demanding placebo-controlled trials, yet the strong psychoactive effects of MDMA-assisted therapy make true blinding impossible. This paper examines neurofunctional mechanisms and methodological challenges relevant to MDMA-assisted therapy research. First, it introduces the Trauma-Affective Memory Loop (TAML), a simple model of how traumatic memories are stored, reactivated, and reinforced through key brain regions. Second, it explains how MDMA works on a neurofunctional level, by reducing fear signals it creates a temporary “*therapeutic window*”. In this state, patients can revisit trauma safely, without being overwhelmed, and reprocess the memory in a healthier way. Third, the paper proposes that different types of trauma exposures respond differently to MDMA-assisted therapy. Acute, one-time traumas may often be resolved within one to three MDMA sessions, while complex or developmental trauma, formed over years, may need repeated and carefully structured treatment. Finally, a proposed clinical-trial framework, the Brinzei MDMA-PTSD Protocol (BMPP), is presented. The framework uses a role-separated, quadruple-masked structure intended to reduce expectancy-related bias while preserving therapeutic fidelity. The aim is to move beyond debates about flawed blinding methods and instead design trials that clarify why MDMA works, for whom it works best, and how to deliver it safely and effectively.

Keywords: MDMA-assisted therapy; PTSD treatment; psychedelic medicine; neurobiological mechanisms; breaking blind

1. Introduction

MDMA-assisted therapy is a highly effective treatment for PTSD¹. Multiple phase II and III trials have demonstrated large, durable reductions in PTSD symptoms²⁻¹⁰, and the therapy is already being adopted in Australia, Israel, United States, Canada, and Switzerland¹¹⁻¹⁵. The effect sizes are substantial, the functional outcomes are clear, and patients are receiving the treatment now. The critical questions are no longer if MDMA is effective, but “*why it is effective?*”, “*for whom it is most effective?*”, and “*how clinical trials can be structured to capture these truths without methodological artefact?*”.

Against this backdrop, the U.S. Food and Drug Administration’s (FDA) recent rejection of MDMA on the grounds of inadequate blinding exposes a deep flaw in regulatory logic¹⁶. It was the FDA itself that initiated a plan in 2002 to develop MDMA as a treatment for PTSD¹⁷. However, as early as 1965, placebo-blinding for psychedelic drug trials was discussed by researchers as methodologically problematic¹⁸. By the early 2000s, leading researchers such as Professor Roland Griffiths had already warned that conventional double-blind methods were inadequate for studying psychedelics in humans^{19, 20}, precisely because their subjective psychoactive effects inevitably compromise masking²¹⁻²³. Instead of engaging collaboratively to adapt methodology, professional and regulatory bodies continued to demand trials using conventional placebo-blinding, knowing it was inadequate²⁴. Decades later, after two full phase III trials and an extension study were completed under these very conditions, the same regulators dismissed the findings based on the expected methodological weakness²⁵. This reflects a methodological inconsistency within current regulatory frameworks: studies were conducted using designs long recognised as vulnerable to functional unblinding, yet those same limitations later became central to regulatory criticism. The hypocrisy is underscored by the FDA’s own 2023 draft guidance for psychedelic trials FDA²⁶, which explicitly acknowledged that placebo-controlled designs are inherently problematic because psychoactive effects compromise blinding²⁷, yet such placebo-controlled phase III trials remain a prerequisite for regulatory approval²⁴. The continued reliance on conventional placebo paradigms may inadvertently delay the development of trial methodologies better suited to psychedelic-assisted therapies. Researchers and regulators must work collaboratively to resolve the blinding methodology issue, rather than perpetuate a cycle of demand and dismissal²⁸.

This paper focuses on neurofunctional mechanisms and methodological considerations relevant to MDMA-assisted therapy. Its aim is fourfold. First, it introduces TAML, a conceptual model of trauma encoding, retrieval, and reconsolidation that isolates the core circuits most relevant to PTSD pathology²⁹. Second, it clarifies what is meant when we say that MDMA “enhances fear extinction”³⁰, that it “decreases amygdala activity”³¹, and that MDMA opens a “therapeutic window”^{32,33}. These phrases are too often repeated without mechanistic clarity. MDMA disrupts functional connectivity (FC) between corticolimbic and self-referential systems³⁴, particularly in the brain regions of the amygdala, anterior cingulate cortex (ACC), hippocampus, insula, dorsolateral prefrontal cortex (DLPFC), and default mode network (DMN)³⁵. During this disruption, threat signalling loses its intrusive dominance, and introspective networks become more available. It is in this repeatable state that reconsolidation can occur. Put simply, a proposed mechanism underlying MDMA-assisted therapy is that MDMA may facilitate a temporary state of reduced defensive responding and increased emotional accessibility. If this therapeutic window is not carefully supported, the patient cannot fully benefit from the medicine.

Third, by integrating the TAML model with MDMA’s neurofunctional effects, I advance a phenotype-specific hypothesis: that acute, discrete traumatic events may be resolved with the standard one-to-three-session MDMA current treatment model, while complex or developmental PTSD, shaped over years of neurodevelopmental adaptation, likely requires longer, scaffolded therapeutic approaches.

Finally, this paper offers a methodological response to the very critique regulators have raised. BMPP employs a role-segregated, quadruple-masked design with epistemic blinding of participants to therapeutic hypotheses³⁶. This framework directly mitigates expectancy effects while preserving therapeutic fidelity, providing trial architecture that psychedelic medicine has long needed.

Current evidence suggests that MDMA-assisted therapy may produce substantial and durable reductions in PTSD symptoms in selected populations. To continue stalling on placebo comparisons and antiquated blinding standards is not scientific caution, it is an abdication of responsibility. The task now is precision, to map mechanisms, stratify phenotypes, and design fit-for-purpose trials that advance health outcomes rather than delay them.

2. Method

This article presents a conceptual translational psychiatry analysis integrating findings from neurobiological PTSD research, MDMA-assisted therapy literature, functional neuroimaging studies, and psychedelic clinical-trial methodology research.

1. A narrative synthesis and mechanistic framework approach were used to:
2. formulate the TAML conceptual model,
3. examine potential neurofunctional mechanisms underlying MDMA-assisted therapy,
4. develop phenotype-specific hypotheses regarding differential PTSD responsiveness,
5. and propose the BMPP as a role-separated masking framework intended to reduce expectancy-related bias in psychedelic clinical trials.

This manuscript is theoretical and methodological in nature and did not involve human participants, clinical intervention, identifiable patient data, or experimental procedures. Institutional ethics approval was therefore not required.

3. A Functional Model of Dysregulated Memory Recall in Trauma

3.1. Mapping the Trauma-Affective Memory Loop

The following section presents TAML, a conceptual model that helps clarify how trauma-related memories may become emotionally charged, persistently reactivated, and difficult to integrate (Figure 2). TAML is intended as a conceptual framework rather than a definitive neurobiological model. Trauma memory processing involves numerous brain regions, neuromodulators, and

systemic interactions that extend beyond the core loop described in TAML³⁷. Nonetheless, by isolating a core circuit involving the hippocampus, ACC, amygdala, and hypothalamus, then following the downstream pathway to the adrenal medulla, the TAML model offers a practical framework for understanding some of the core dysfunctions underlying trauma recall and emotional dysregulation.

Trauma encoding refers to the process by which the nervous system stores salient aspects of an overwhelming or threatening experience³⁸. This includes sensory-perceptual information, spatial and temporal context, emotional states, autonomic responses, and unprocessed affect that may remain dormant but reactive.

Trauma retrieval and reconsolidation describes the process through which a stored traumatic memory is 'reactivated', often in response to environmental cues, the memory once recalled becomes temporarily labile, to be restabilised in memory by updating, modifying, or disrupting the trauma³⁹. If the affective tone is not updated in a safe context, the memory may reconsolidate with its original emotional charge intact or worsen, with greater negative affective valence, perpetuating maladaptive responses. This is the loop aspect of TAML.

As we explore the neuropsychological mechanisms of MDMA, the TAML framework provides a conceptual scaffold for mapping how these mechanisms may interact with TAMLs, enabling the formulation of targeted hypotheses about MDMA's differential efficacy across specific phenotypes of PTSD.

3.2. From Context to Crisis: Memory Retrieval and Affective Appraisal

The ACC is a key brain region involved in emotion regulation, attention, and the integration of affective experiences into retrieval of autobiographical memory⁴⁰. It acts as a bridge between feeling and remembering⁴¹, determining the emotional relevance of an experience linked via memory circuits from the hippocampus to the ACC⁴², then sending information from the ACC to the amygdala⁴³. In the context of trauma, this function can become maladaptive, potentially leading to the development of PTSD^{44,45}.

3.3. Trauma as an Adaptive Response of the Amygdala

Trauma is not solely the consequence of external events but is fundamentally rooted in the affective state experienced by the nervous system at the time of the event, states such as helplessness, terror, betrayal, or abandonment⁴⁶. The amygdala, a limbic structure central to the detection of emotional salience, particularly threat, encodes these affective experiences as dangerous⁴⁴. It subsequently adapts by sensitising the individual's nervous system to similar internal states, activating the sympathetic nervous system (SNS) as a protective response when those affective patterns re-emerge.

Notably, the amygdala-ACC circuit does not encode episodic detail but rather affective valence⁴⁷. While much of the literature refers to "*emotional information*" in the context of memory encoding, this typically denotes external stimuli that elicit emotional responses⁴⁸. In the current trauma-framework, the focus is on internal affective states; physiological-emotional configurations that the amygdala-ACC circuit uses to guide salience detection and threat reactivity⁴⁹. Its function in this context is not to recall the specific content of a past event, but to detect and respond to reoccurring internal affective states associated with prior threat⁵⁰. In essence, it operates on a heuristic akin to: "*this internal state once co-occurred with danger, if it arises again, initiate defensive mechanisms*".

Rather than reflecting a dysfunction or adaptation, this represents the amygdala's core functional role in affective pattern recognition and threat detection⁵¹. In PTSD, this mechanism becomes sensitised, triggering disproportionate or misaligned threat responses in the absence of actual danger⁴⁴, a pattern described in the TAML model. TAML frames this process as a kind of feedback loop, where reactivation of a prior affective state amplifies the emotional memory network and maintains the sense of threat even when no external danger is present. This framework also provides a foundation for linking TAML to the current understanding of MDMA's neurobiological

mechanisms and how they modulate trauma-related processes; processes that will be explored later in this paper.

3.4. The Role of the ACC in Triggering the Adaptive Response of the Amygdala

As outlined in TAML, the ACC compares present affective states to past traumatic imprints. When they resemble, it reactivates the amygdala and sympathetic cascade, perpetuating PTSD responses^{52, 53}. This neural mechanism exemplifies how trauma-related affective conditioning can perpetuate dysregulated physiological and psychological responses in the absence of actual threat.

3.5. Affective Fusion: When Emotion Becomes Identity

Beyond threat appraisal, the ACC contributes to self-referential meaning, explaining why trauma-related states can fuse with identity⁵⁴. Functional Magnetic Resonance Imaging (fMRI) studies have particularly found that the rostral substructure of the ACC (rACC) is engaged during negative self-referential processing⁵⁵. Over time, these affective imprints may shift from transient emotional states to egosyntonic identity structures. That is, the individual no longer merely experiences fear, but comes to identify with it: “I am unsafe”, “I am broken”, “I am unworthy”. This fusion of affect and identity forms a psychological trap, in which emotionally conditioned neural patterns are mistaken for intrinsic selfhood, thereby perpetuating dysregulation and obstructing integration or healing.




Figure 1. Dis-identification: interrupting trauma-driven affective loops by recognising emotions as states rather than identity.

3.6. Dis-Identification and the Deconstruction of Affective Imprints

Psychological healing begins with the capacity to bring conscious awareness to the affective signature that the ACC has associated with a traumatic memory⁵⁶. This signature is not usually recalled as a discrete memory but as an implicit affective tone, a felt state of fear, shame, or helplessness, that dominates perception and behaviour when left unexamined⁵⁷. Over time, such affective tones can become egosyntonic, fusing with identity. Dis-identification interrupts this fusion, shifting perspective from “this is me” to “this is a state I am experiencing”, enabling neural and psychological restructuring⁵⁸. This distinction is crucial, when the self is equated with trauma, every recurrence of affective arousal reinforces the trauma schema. By stepping back into observation, the individual introduces psychological distance between the arising affect and their core identity.

This decoupling allows both neural and psychological restructuring⁵⁹. On the neural level, repeated observation of affect without immediate defensive mobilisation weakens the overlearned FC between the ACC, amygdala, and DNM, reducing the likelihood of automatic hyperarousal. On

the psychological level, dis-identification opens the possibility of new self-narratives, where traumatic states are reframed as experiences rather than identities⁶⁰. This process is not about denying the trauma but about reclaiming agency in the face of it, recognising that while the affective imprint was once a survival response, it no longer needs to define the self in the present.




Figure 2. Diagrammatic representation of TAML illustrating the conceptual model of the neurobiological mechanisms by which benign environmental cues trigger PTSD episode activation.

4. Neuropsychopharmacology of MDMA

4.1. Affective Circuitry Modulation in MDMA-Assisted Therapy

This section does not revisit the well-known pharmacodynamics of MDMA on serotonin, dopamine, and oxytocin systems. Instead, it highlights a less discussed but crucial element: how MDMA changes network-level activity in the corticolimbic system, especially amygdala–ACC FC that underpins trauma-related affective memory, threat detection, and emotional appraisal ⁶¹.

4.2. Corticolimbic Decoupling and Salience Recalibration

Neuroimaging confirms the amygdala–ACC threat loop described in TAML: amygdala hyperactivity paired with biased ACC appraisal ^{44, 62}.

MDMA may transiently modulate components of this loop. Imaging studies show decreased amygdala hyperactivity alongside increased ACC engagement ^{34, 63}. Importantly, these are related but separable mechanisms:

- **Decreasing amygdala hyperactivity:** MDMA directly dampens the amygdala’s excitability and weakens its bottom-up output to the hypothalamus ⁶⁴, reducing the body’s automatic fear-driven reactions.
- **Enhancing fear extinction:** By modulating amygdala–ACC FC, MDMA raises the threshold for the ACC to classify a stimulus as threatening ^{35, 65, 66}. This recalibration allows traumatic memories to be revisited without triggering the defensive sympathetic cascade, creating the conditions for extinction learning.

Together, this corticolimbic decoupling reduces the flow of exaggerated fear signals and recalibrates affective salience. The individual can engage with traumatic material in a more regulated state, without being overwhelmed ⁶⁷.

In sum, “*decreasing amygdala hyperactivity*” and “*enhancing fear extinction*” describe distinct but synergistic effects. One suppresses the raw intensity of fear signals; the other alters how those signals are interpreted and integrated. This dual action, combined with the loosening of DMN dominance, defines MDMA’s therapeutic window, a temporary brain state where trauma can be processed safely and constructively to create new self-referential introspection.

4.3. The Therapeutic Window: Self-Referential Network Remapping and Affective Decoupling

Beyond fear extinction, MDMA alters DMN activity, especially in circuits tied to self-referential processing and autobiographical meaning-making ^{68, 69}. Under unresolved trauma, affective states such as shame or fear are embedded within the ACC–DMN–insula network as enduring identity structures: “*I am unsafe*”, “*I am broken*”. These are not simply thoughts but embodied self-states, reinforced by neural circuitry.

MDMA facilitates a transient decoupling of affect from self-schema ⁷⁰. With the amygdala–ACC circuit less likely to misclassify interoceptive affect as threat, defensive amygdala intrusion recedes. In this quieter state, the insula’s interoceptive signals can rise to conscious awareness ³⁵. This represents a period of insula upregulation, when interoceptive input carries more weight than fear-conditioned affect.

- **This is the therapeutic window:** a brain state where emotional and affective states can be observed rather than fused with, enabling metacognitive awareness. Within this altered context, traumatic memories can be re-encountered without defensive mobilisation. Instead, they are re-encoded against a backdrop of coherence, empathy, and agency. Over repeated exposures, the traumatic imprint shifts from a danger-laden signal to a survivorship narrative, supporting integration.

4.4. Role of the Prefrontal Cortex in Supporting Integration

During this process, the prefrontal cortex (PFC) supports integration by providing reflective and rational scaffolding for the raw interoceptive signals emerging from the insula, particularly via the insula–DLPFC circuit³⁵. While not the primary driver of therapeutic change, the PFC works in concert with ACC recalibration and insula upregulation, enabling the individual to link felt bodily states with higher-order meaning. This network synergy allows emotional experiences to be observed without fusion, reinterpreted within a safe context without amygdala intrusion, and then woven into a coherent self-narrative. The potency of MDMA-assisted therapy lies in the integrative process of insula-driven anchoring of new affective states, concurrent with amygdala–ACC circuit recalibration to reduce maladaptive threat appraisal, while the PFC helps organise these shifts into a survivable and adaptive identity structure. In this way, cognition does not override emotion but instead supports the consolidation of new learning, ensuring that re-encoded traumatic memories can be stably integrated into a broader narrative of recovery.

5. The Brinzei MDMA-PTSD Protocol

5.1. Formulating the Hypothesis

The central neurobiological hypothesis of this protocol is that MDMA-assisted therapy is most effective when trauma is encoded as an acute affective imprint, typically arising from single-event or time-bound exposures. In such cases, the dysregulated circuitry, principally the amygdala–ACC circuit, can often be recalibrated through one to three well-structured MDMA sessions.

Under MDMA, amygdala hyperactivity is dampened, reducing fear signals, while the ACC recalibrates salience appraisal, and the insula brings interoceptive signals to awareness without being hijacked by defensive responses³⁵. The PFC then provides reflective scaffolding, enabling traumatic memories to be re-encoded as survivable experiences within a coherent self-narrative. For acute trauma phenotypes, this network-level modulation can rapidly reorganise the trauma loop, producing durable resolution.

By contrast, complex or developmental PTSD arises from years of chronic threat, relational neglect, or environmental adversity⁷¹. Here, trauma is not a discrete imprint but has shaped self-referential networks, embedding dysregulation into the DMN, ACC, and insula over neurodevelopmental time^{72,73}. In these cases, MDMA's neuromechanisms while still catalytic in generating windows of metacognitive clarity, embodied safety, and affective recontextualisation are unlikely to produce full reorganisation within one to three sessions. Instead, repeated, scaffolded interventions are required, with MDMA acting as a facilitator of long-term neural and psychological integration.

This distinction between acute and complex trauma is thus neuroarchitectural. It reflects differences in how memories are encoded and embedded across corticolimbic and self-referential systems. This neuroarchitectural distinction should guide both therapeutic design and clinical expectations.

5.2. Differentiating Trauma Exposure: Neurobiological Implications for MDMA-Assisted Therapy

5.2.1. Neurophenomenological Stratification of Trauma Exposure

To refine the clinical use of MDMA-assisted therapy, trauma must be differentiated not only by symptoms but by the underlying encoding architecture. The following formulations represent a working model to guide precision-targeted interventions, acknowledging the need for empirical validation.

5.2.2. Direct Exposure and Affective Traceability

Acute, direct traumas such as combat, assault, or catastrophic injury tend to create sharply defined imprints within the corticolimbic system ⁷⁴, particularly in the amygdala–ACC circuit. In these cases, the amygdala assigns intense salience to the threat ⁵¹, while the ACC integrates this salience into autobiographical memory and continues to appraise its relevance over time ⁴¹. This combination produces a clear trauma trace that can be readily reactivated and is strongly linked to TAML.




Figure 3. Amygdala–ACC circuit in PTSD: dysregulated connectivity drives salience misclassification and defensive mobilisation.

MDMA facilitates resolution of these imprints through several complementary mechanisms. It downregulates the amygdala, dampening bottom-up fear signals, and recalibrates the ACC, allowing more accurate reappraisal and extinction of threat associations ⁶¹. At the same time, it upregulates the insula, enabling interoceptive states to rise into awareness without sympathetic flooding, while the PFC provides reflective scaffolding, weaving these revised affective states into a coherent and survivable narrative ³⁵. Together, these network-level effects enable affective decoupling, in which the traumatic memory can be revisited without overwhelming physiological responses, permitting reconsolidation within a safer and more adaptive emotional frame ⁶⁶. Acute trauma phenotypes may align more closely with the proposed neuromechanisms of MDMA-assisted therapy and could potentially respond more favourably to limited-session interventions.




Figure 4. MDMA's network-level effects: amygdala downregulation, ACC recalibration, insula upregulation, and PFC scaffolding enable safe trauma reconsolidation.

5.2.3. Indirect Exposure and Affective Enmeshment

Not all trauma comes from a single, sudden event ⁷⁵. For many people, trauma builds up gradually through relationships, caregiving, neglect, or long-term exposure to someone else's suffering ⁷⁶. This is called relational, vicarious, or developmental trauma, referred to as enmeshment trauma ⁷⁷. Unlike direct trauma, which creates a sharp 'imprint' in the amygdala–ACC loop, this type of trauma spreads across broader brain systems that deal with identity, empathy, and self-concept.

Enmeshed trauma develops when the brain's empathy networks, particularly when the mirror neurons and insula cause another person's suffering to be felt almost as if it were one's own ⁷⁸. Over time, this repeated resonance blurs the boundaries between self and other. The ACC and DMN then consolidate these emotions into self-identity, embedding guilt, helplessness, or shame so deeply that they stop being temporary states and instead become enduring self-concepts ⁷⁹. Meanwhile, the amygdala, which typically responds to immediate threat, becomes hypersensitized, misinterpreting interpersonal conflict or reminders of others' pain as signals of danger. These interacting processes generate TAML that perpetually reactivates distress. Unlike direct trauma, where the loop is tied to a specific memory trace, enmeshed trauma binds the loop to relationships and identity itself, making it both more diffuse and more resistant to resolution.




Figure 5. Enmeshment trauma: mirror neuron and insula resonance blur self–other boundaries, consolidated by ACC and DMN into identity structures.

MDMA interrupts the cycle of enmeshed trauma by modulating the very brain networks that sustain it⁶¹. First, it reduces amygdala dominance, quieting the exaggerated fear responses that usually arise in relational contexts³⁴. This calming effect prevents the nervous system from defaulting to defensive arousal when interpersonal cues are encountered. At the same time, MDMA increases the flexibility of the ACC, allowing it to reappraise emotional signals more accurately, distinguishing sadness or frustration from immediate threat. The loosening of DMN patterns further enables negative self-beliefs such as “*I am unworthy*” or “*I am broken*” to be decoupled from identity⁵⁸, shifting them from fixed truths into transient experiences that can be observed with psychological distance. Finally, MDMA enhances oxytocin-mediated social safety⁸⁰, fostering a sense of trust and empathic connection that allows engagement with others without becoming emotionally enmeshed in their pain⁸¹. In terms of TAML, these combined effects soften the amygdala–ACC–DMN feedback cycle, creating temporary windows of safety and clarity in which entrenched relational patterns can be reprocessed⁸². Although such windows rarely dismantle enmeshed trauma in a single session, their repeated occurrence through structured therapy gradually rewires identity-level dysregulation and supports long-term integration.




Figure 6. MDMA modulation of enmeshment trauma: quiets amygdala hyperreactivity, recalibrates ACC appraisal, loosens DMN-based self-fusion, and enhances oxytocin-mediated social safety.

These mechanisms create temporary conditions for insight and recontextualisation⁶⁷, but because the trauma is relationally embedded and not affectively autonomous, resolution is less immediate. Here, MDMA functions as a recurrent catalyst within a longer therapeutic arc, gradually restructuring identity-level dysregulation.

5.2.4. Clinical Implications

This proposed stratification, between direct affective traceability and relational enmeshment, has implications for treatment planning. While individuals with acute, direct trauma may benefit significantly from short-course MDMA interventions, those with developmental, relational, or cumulative trauma may require multi-modal, phased therapeutic models. It must be emphasised that this distinction is based on a neurophenomenological hypothesis, not a validated biomarker system.

Table 1. Hypothesised associations between trauma exposure and MDMA responsiveness.

Trauma Type	PTSD Phenotype	Nature of Exposure	Affective Encoding Profile	MDMA Therapeutic Potential
Acute direct trauma	Classic PTSD	First-hand, time-bound	Amygdala–ACC circuit; discrete imprint	High; rapid decoupling and re-encoding
Chronic direct trauma	Complex PTSD	Sustained, developmental	Multi-network dysregulation (ACC, DMN)	Moderate; requires extended integration
Witnessed trauma ^a	Secondary PTSD	Vicarious, empathic	Partial co-activation, less personal	Moderate; depends on identity fusion

Witnessed trauma ^b	Relational PTSD	Deeply personal, empathic	Affective enmeshment, insula/ACC load	Variable; depends on healing in the other
Repeated exposure ^c	Occupational PTSD	Chronic, cumulative	Layered micro-trauma, moral injury	Moderate; may require phased intervention

^aWitnessed trauma of a stranger; ^bWitnessed trauma of a loved one; ^cRepeated occupational trauma, ie. police.

6. Methodological Foundations of Masking Design

6.1. Clinical Rationale for Expectancy Control

The masking strategy employed in BMPP is designed to preserve internal validity by mitigating expectancy effects and minimising sources of expectancy bias. In studies involving MDMA-assisted therapy, the FDA have made clear that expectancy from breaking-blind is not merely a nuisance variable but a core methodological concern FDA²⁶. Participant expectations, therapeutic framing, and assessor interpretation can each influence outcome measures, particularly when these outcomes are subjective or phenomenologically rich ²⁷.

Masking in this context is designed to control for expectancy effects across relevant trial stakeholders, preserving the methodological conditions necessary for reliable causal inference. By limiting access to information about the specific therapeutic hypotheses or predicted response patterns, the proposed protocol maintains a controlled interpretive environment that reduces the influence of demand characteristics, placebo effects, and observer-expectancy bias.

6.2. Role-Based Masking Justification

To minimise expectancy and observer bias, BMPP employs a role-specific masking framework. All participants receive the same intervention, but they are stratified by trauma phenotype. Participants are masked to the protocol's therapeutic hypothesis and to their own phenotype classification to reduce demand characteristics and placebo effects. Care providers and outcome assessors are masked to trauma phenotype to ensure unbiased support and outcome measurement. Therapists, who must tailor treatment to the participant's trauma profile, are unmasked but restricted from outcome assessment and analysis. Investigators remain masked to participant phenotype while retaining knowledge of the study's mechanistic rationale. This structure results in a quadruple-masked design.

Table 2. Role-masking protocol matrix.

Role	Masked To	Rationale
Participants	Phenotype classification; Therapeutic hypothesis	Reduces expectancy effects and demand characteristics
Care Providers	Phenotype classification	Prevents bias in supportive care delivery
Outcome Assessors	Phenotype classification	Ensures objectivity in clinical outcome assessment
Therapists	<i>Not blinded</i>	Must know phenotype and rationale to deliver targeted psychotherapy
Investigators	Phenotype classification	Preserves analytic objectivity while maintaining scientific oversight

6.3. Masking Integrity: Role Conflict Management

To preserve the methodological integrity of the trial, BMPP enforces strict role separation to minimise the risk of unintentional unmasking and mitigate expectancy-related bias. Because access to specific information, such as trauma phenotype or therapeutic rationale, can compromise masking, individuals in roles that require such access (therapists) must be clearly segregated from those responsible for outcome assessment, recruitment, or data analysis. Therapists must understand the participant's trauma presentation to deliver tailored psychotherapy and are therefore incompatible with blinded functions⁸³. Recruiters, if involved in study screening or consent processes, may inadvertently acquire knowledge of participant phenotype or trial rationale; as such, they are excluded from therapeutic, analytical, or assessment duties and functionally isolated from outcome data. Investigators, who design and oversee the study, are masked to trauma phenotype to prevent analytical bias and ensure objective interpretation. They may access treatment assignment only when required for safety monitoring or compliance but are restricted from therapeutic or participant-facing roles. This deliberate separation of responsibilities is designed to prevent role conflicts from undermining the masking strategy and to ensure that any observed therapeutic effects reflect genuine treatment impact rather than bias introduced through role contamination or expectancy effects.

Table 3. Rationale for role masking.

Role	Excluded Function	Access Restrictions
Therapist	Cannot act as investigator, recruiter, care provider, or outcome assessor	Access to trauma phenotype and rationale; excluded from assessment and analysis
Recruiter	Cannot act as therapist, care provider, outcome assessor, or data-analysing	Blinded to phenotype where possible; firewalled if also acting in investigator role
Investigator	Cannot act as therapist, recruiter, care provider, or outcome assessor	Masked to phenotype; may access treatment data for monitoring; no direct participant contact

7. Discussion

Several limitations should be acknowledged. TAML and BMPP are conceptual and methodological frameworks that require empirical validation. The proposed neurophenomenological stratification model remains hypothetical and should not be interpreted as a validated clinical classification system. Additionally, many proposed neurofunctional mechanisms discussed in this paper remain inferential and require prospective investigation.

The evidence increasingly supports MDMA-assisted therapy (MDMA-assisted therapy) as a potent intervention for PTSD, though its efficacy may be contingent upon the nature and neurobiological imprint of the trauma¹. PTSD is a heterogeneous disorder: some individuals develop symptoms in response to discrete, time-bound events, while others suffer from chronic, relational, or developmental exposures that permeate identity and relational schemas⁸⁴. This variability may help explain differential treatment outcomes.

Conventional pharmacological strategies for PTSD have often focused on adrenergic antagonism, particularly through the use of α 1-adrenergic receptor (α 1) inverse agonists such as prazosin (Minipress®)⁸⁵, or α 1 antagonists such as doxazosin (Cardura®), and terazosin (Hytrin®)^{86,87}. These agents blunt the sympathetic cascade at its terminal effector level, blocking norepinephrine and epinephrine activity on central and peripheral α 1 receptors, thereby reducing symptoms such as hypervigilance, nightmares, and autonomic arousal⁸⁸. While sometimes effective, this approach operates at the bottom level of the sympathetic cascade, targeting the expression of symptoms rather than the upstream affective circuitry in which the traumatic memory is encoded⁸⁹. In other words, α 1 antagonists provide a form of symptomatic palliation, they reduce the physiological

manifestations of trauma-related hyperarousal but do little to alter the maladaptive circuits that sustain PTSD. By contrast, MDMA allows a therapeutic window where traumatic memories to be re-experienced in a safe neurochemical context and re-encoded with reduced fear salience^{35, 44, 67}. Importantly, MDMA does not forgo adrenergic modulation altogether, by dampening amygdala–hypothalamic threat signalling upstream⁶⁴, the sympathetic cascade is never fully mobilised, meaning that $\alpha 1$ receptors are not driven by excessive epinephrine in the first place. This represents, in effect, a form of functional $\alpha 1$ antagonism that MDMA provides, the benefit of adrenergic quieting without the need for direct receptor blockade, while simultaneously enabling higher-order processes that conventional antagonists cannot achieve. Thus, MDMA combines the symptomatic relief traditionally sought through $\alpha 1$ blockade with the deeper neurobiological effects of network recalibration, including amygdala–ACC–insula FC disruption, DMN modulation, and oxytocin-mediated pro-social signalling⁹⁰. In this sense, $\alpha 1$ antagonists reflect an earlier-generation approach that addresses symptoms alone, whereas MDMA-assisted therapy may represent a potentially important shift in trauma-focused psychiatric treatment by simultaneously modulating sympathetic arousal and supporting trauma-related memory integration. A related class of conventional interventions involves $\alpha 2$ -adrenergic receptor ($\alpha 2$) agonists such as clonidine (Catapres®), guanfacine (Tenex®, Intuniv®), and dexmedetomidine (Precedex®). $\alpha 2$ agonists pursue the same principle from the opposite end of the cascade, reducing adrenergic output presynaptically^{91–93}. Like $\alpha 1$ antagonists, they mute sympathetic overdrive and provide relief of insomnia, hyperarousal, and startle responses. Yet, they too leave untouched the amygdala–ACC–insula circuitry where trauma is encoded. $\alpha 1$ antagonists and $\alpha 2$ agonists represent earlier-generation approaches: they quiet adrenergic tone but cannot open the therapeutic window required for trauma reconsolidation^{94, 95}. Moreover, chronic suppression of noradrenergic tone can be sedating and cognitively dulling, limiting tolerability for some patients⁹⁶. By contrast, MDMA simultaneously dampens adrenergic signalling upstream (preventing $\alpha 1$ drive in the first place), modulates corticolimbic connectivity, and enhances interoceptive and pro-social networks. MDMA also works downstream, agonising $\alpha 2$ itself^{97, 98}, working at all levels as an ‘entourage effect’, further explaining MDMA’s superiority over conventional adrenergic agents.

Neurobiologically, MDMA attenuates hyperactive amygdala signalling while enhancing ACC regulation and insula-mediated interoception^{34, 35, 99}. This recalibration is particularly suited to trauma encoded as acute affective imprints, where hyperarousal, hypervigilance, and intrusive re-experiencing are dominant. In these cases, MDMA facilitates affective decoupling and re-encoding of the traumatic memory in a regulated state, often within just a few sessions.

However, in complex or relational PTSD, trauma is not a single memory trace but a developmental architecture^{75, 76}. Here, TAML highlights how affective imprints shift from transient defensive states into enduring self-referential structures: “*I am unsafe*” or “*I am unworthy*”. For such individuals, MDMA may assist in reducing fear responses and fostering self-compassion, but resolution also requires extended therapeutic work, relational repair, grief integration, and existential processing of powerlessness¹⁰⁰. This distinction underscores that MDMA is not a universal cure, but a catalyst best matched to certain PTSD phenotypes⁹⁴.

Emerging neuroimaging findings support this stratification. For example, adolescents exposed to the 2013 Boston Marathon bombing with heightened amygdala reactivity and reduced hippocampal engagement during regulation tasks were more likely to develop PTSD¹⁰¹. Such pre-existing neural vulnerabilities map onto the TAML model, suggesting that individual neurobiological profiles may predict therapeutic responsiveness. Personalising treatment according to trauma type and neural phenotype therefore represents the next frontier in MDMA-assisted therapy.

8. Conclusions

BMPP is proposed as a conceptual framework intended to support more precise and methodologically robust investigation of MDMA-assisted therapy for PTSD, particularly in trauma presentations characterised by discrete and affectively traceable memory structures. When the

traumatic imprint resides primarily in heightened sympathetic responses, MDMA can rapidly recalibrate defensive circuits, allowing memories to be re-encoded without fear dominance.

By contrast, when trauma is relationally entangled or developmentally embedded, MDMA may provide essential affective safety but requires integration within longer-term psychotherapeutic frameworks. Healing in these cases depends not only on neurobiological decoupling but also on reconstructing meaning, repairing relationships, and processing existential loss.

Thus, the efficacy of MDMA hinges on the ownership and localisation of the traumatic wound, whether it lies in the individual's own nervous system or in unresolved relational fields. By distinguishing these pathways, BMPP offers a roadmap for tailoring psychedelic therapy to the complexity of trauma. As prospective trials integrate symptom profiling with neuroimaging and the TAML framework, future integration of symptom profiling, neuroimaging, and mechanistic models may contribute to more individualised approaches to MDMA-assisted therapy for PTSD.

BMPP represents a significant step forward in the tailored application of MDMA-assisted therapy for PTSD. By distinguishing between different types of trauma exposure and understanding the underlying neural mechanisms, we can better identify those who will benefit most from this promising treatment. This personalised approach not only maximises therapeutic outcomes but also paves the way for future innovations in the field of psychedelic medicine. As research continues, this methodology holds the potential to transform the landscape of PTSD treatment, offering hope and healing to countless individuals. Declaration of conflicting interests.

The author declares a financial interest in consulting services provided to psychiatrists seeking Authorised Prescriber (AP) approval for the use of MDMA in clinical practice. This work has the potential to generate financial benefit for the author through such consulting activities.

Author Contributions: The sole author, Octavian Victor Brinzei, conceived the study, developed the theoretical framework, conducted the literature review, performed the analysis and interpretation, and wrote the manuscript in its entirety. The author was solely responsible for drafting, revising, and approving the final version of the manuscript.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The article processing charge (APC) for publication was funded by Mind Medicine Australia.

Acknowledgments: The author gratefully acknowledges Flint Rehab (www.flintrehab.com) as the original source of selected brain image elements that supported the development and visual articulation of the Trauma-Affective Memory Loop (TAML). These image components were used in a limited and highly selective manner and were substantially transformed through synthesis, annotation, and integration into a novel conceptual framework, generating new meaning for the purposes of scholarly analysis, psychoeducation, and scientific communication. Their use was non-substitutive and consistent with international fair use principles and Australian copyright fair dealing provisions for research, criticism and review, reporting, explanation, and education. The author thanks Mind Medicine Australia for formative professional experiences that facilitated learning in the field of psychedelic medicine. The author is also grateful to Australian psychiatrists whose clinical inquiries necessitated the development of psychoeducational materials, thereby motivating deeper investigation into MDMA-Assisted Therapy (MDMA-assisted therapy). Regulatory guidance and professional discourse from the Therapeutic Goods Administration (TGA) and Australian medical and health bodies are also acknowledged as influential in shaping the mechanistic and translational perspectives presented.

Ethical Statement: This manuscript was prepared in accordance with the *Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals* formulated by the International Committee of Medical Journal Editors (ICMJE). This article did not involve the collection of new data from human participants or animals, and therefore did not require institutional ethics committee approval or informed consent.

References

1. Slomski A. MDMA-Assisted Therapy Highly Effective for PTSD. *JAMA* 2021; 326: 299-299. DOI: 10.1001/jama.2021.11748.
2. Christie D, Yazar-Klosinski B, Nosova E, et al. MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder. *Front Psychiatry* 2022; 13: 939302. 20221103. DOI: 10.3389/fpsy.2022.939302.
3. Jardim AV, Jardim DV, Chaves BR, et al. 3,4-methylenedioxyamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: an open label pilot study in Brazil. *Braz J Psychiatry* 2021; 43: 181-185. DOI: 10.1590/1516-4446-2020-0980.
4. Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. *Nat Med* 2021; 27: 1025-1033. 20210510. DOI: 10.1038/s41591-021-01336-3.
5. Mitchell JM, Ot'alora GM, van der Kolk B, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. *Nat Med* 2023; 29: 2473-2480. 20230914. DOI: 10.1038/s41591-023-02565-4.
6. Mithoefer MC, Wagner MT, Mithoefer AT, et al. The safety and efficacy of (+/-)3,4-methylenedioxyamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. *J Psychopharmacol* 2011; 25: 439-452. 20100719. DOI: 10.1177/0269881110378371.
7. Mithoefer MC, Mithoefer AT, Feduccia AA, et al. 3,4-methylenedioxyamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. *Lancet Psychiatry* 2018; 5: 486-497. 20180501. DOI: 10.1016/S2215-0366(18)30135-4.
8. Oehen P, Traber R, Widmer V, et al. A randomized, controlled pilot study of MDMA (+/- 3,4-Methylenedioxyamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). *J Psychopharmacol* 2013; 27: 40-52. 20121031. DOI: 10.1177/0269881112464827.
9. Ot'alora GM, Grigsby J, Poulter B, et al. 3,4-Methylenedioxyamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. *J Psychopharmacol* 2018; 32: 1295-1307. 20181029. DOI: 10.1177/0269881118806297.
10. Wang JB, Lin J, Bedrosian L, et al. Scaling Up: Multisite Open-Label Clinical Trials of MDMA-Assisted Therapy for Severe Posttraumatic Stress Disorder. *Journal of Humanistic Psychology* 2021: 00221678211023663. DOI: 10.1177/00221678211023663.
11. Avanceña ALV, Kahn JG and Marseille E. The Costs and Health Benefits of Expanded Access to MDMA-assisted Therapy for Chronic and Severe PTSD in the USA: A Modeling Study. *Clinical Drug Investigation* 2022; 42: 243-252. DOI: 10.1007/s40261-022-01122-0.
12. Brnzei OV, Donley CN and Dixon Ritchie G. From prohibited to prescribed: The rescheduling of MDMA and psilocybin in Australia. *Drug Science, Policy and Law* 2023; 9: 20503245231198472. DOI: 10.1177/20503245231198472.
13. Karp Barnir E, Rubinstein Z, Abend R, et al. Peri-traumatic consumption of classic psychedelics is associated with lower anxiety and post-traumatic responses 3 weeks after exposure. *J Psychopharmacol* 2025; 39: 1031-1036. 20250421. DOI: 10.1177/02698811251334025.
14. Mocanu V, Mackay L, Christie D, et al. Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy. *Substance Abuse Treatment, Prevention, and Policy* 2022; 17: 37. DOI: 10.1186/s13011-022-00468-0.
15. Oehen P and Gasser P. Using a MDMA- and LSD-Group Therapy Model in Clinical Practice in Switzerland and Highlighting the Treatment of Trauma-Related Disorders. *Front Psychiatry* 2022; 13: 863552. 20220425. DOI: 10.3389/fpsy.2022.863552.
16. Roseman L. A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy. *Journal of Psychopharmacology* 2025; 39: 313-315. DOI: 10.1177/02698811241309611.

17. Doblin R. A Clinical Plan for MDMA (Ecstasy) in the Treatment of Posttraumatic Stress Disorder (PTSD): Partnering with the FDA. *Journal of Psychoactive Drugs* 2002; 34: 185-194. DOI: 10.1080/02791072.2002.10399952.
18. Metzner R, Litwin G and Weil G. The relation of expectation and mood to psilocybin reactions: a questionnaire study. *Psychodelic Rev* 1965; 5: 3-39.
19. Griffiths RR, Richards WA, McCann U, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. *Psychopharmacology (Berl)* 2006; 187: 268-283; discussion 284-292. 20060707. DOI: 10.1007/s00213-006-0457-5.
20. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *J Psychopharmacol* 2016; 30: 1181-1197. DOI: 10.1177/0269881116675513.
21. Aday JS, Heifets BD, Pratscher SD, et al. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. *Psychopharmacology* 2022; 239: 1989-2010. DOI: 10.1007/s00213-022-06123-7.
22. Butler M, Jelen L and Rucker J. Expectancy in placebo-controlled trials of psychedelics: if so, so what? *Psychopharmacology* 2022; 239: 3047-3055. DOI: 10.1007/s00213-022-06221-6.
23. Hovmand OR, Poulsen ED, Arnfred S, et al. Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review. *Journal of Psychopharmacology* 2023; 37: 649-659. DOI: 10.1177/02698811231180276.
24. Doblin RE, Christiansen M, Jerome L, et al. The Past and Future of Psychedelic Science: An Introduction to This Issue. *Journal of Psychoactive Drugs* 2019; 51: 93-97. DOI: 10.1080/02791072.2019.1606472.
25. Wilkinson ST and Sanacora G. Issues in Clinical Trial Design—Lessons From the FDA’s Rejection of MDMA. *JAMA Psychiatry* 2025; 82: 545-546. DOI: 10.1001/jamapsychiatry.2025.0442.
26. Food and Drugs Administration (FDA). Psychedelic Drugs: Considerations for Clinical Investigations, <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations> (2023).
27. Harris E. FDA Proposes First Guidance for Researchers Studying Psychedelics. *JAMA* 2023; 330: 307-307. DOI: 10.1001/jama.2023.12058.
28. Schenberg EE. From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence-Based Policy and Practice. *Pharmacology Research & Perspectives* 2025; 13: e70097.
29. Brinzei OV. Trauma-Effective Memory Loop, <https://psynergeticsciences.com.au/blogs/neuroscience/trauma-effective-memory-loop> (2025).
30. Feduccia AA and Mithoefer MC. MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? *Prog Neuropsychopharmacol Biol Psychiatry* 2018; 84: 221-228. 2018/03/11. DOI: 10.1016/j.pnpbp.2018.03.003.
31. Johansen P and Krebs T. How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. *Journal of Psychopharmacology* 2009; 23: 389-391. DOI: 10.1177/0269881109102787.
32. Huestis MA, Smith WB, Leonowens C, et al. MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model-informed analysis. *CPT: Pharmacometrics & Systems Pharmacology* 2025; 14: 376-388.
33. O’Brien S and Nutt D. MDMA-assisted therapy: challenges, clinical trials, and the future of MDMA in treating behavioral disorders. *CNS spectrums* 2025; 30: e15.
34. Singleton SP, Wang JB, Mithoefer M, et al. Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder. *Front Psychiatry* 2022; 13: 947622. 20230112. DOI: 10.3389/fpsy.2022.947622.
35. Walpola IC, Nest T, Roseman L, et al. Altered Insula Connectivity under MDMA. *Neuropsychopharmacology* 2017; 42: 2152-2162. 20170214. DOI: 10.1038/npp.2017.35.
36. Brinzei OV. The Brinzei MDMA-PTSD Protocol, <https://psynergeticsciences.com.au/blogs/neuroscience/brinzei-mdma-ptsd-protocol> (2025).
37. Morris KR, Jaeb M, Dunsmoor JE, et al. Decoding threat neurocircuitry representations during traumatic memory recall in PTSD. *Neuropsychopharmacology* 2025; 50: 568-575. DOI: 10.1038/s41386-024-02028-5.

38. Maddox SA, Hartmann J, Ross RA, et al. Deconstructing the Gestalt: Mechanisms of Fear, Threat, and Trauma Memory Encoding. *Neuron* 2019; 102: 60-74. DOI: 10.1016/j.neuron.2019.03.017.
39. Chiamulera C, Hinnenthal I, Auber A, et al. Reconsolidation of maladaptive memories as a therapeutic target: pre-clinical data and clinical approaches. *Front Psychiatry* 2014; 5: 107. 20140819. DOI: 10.3389/fpsy.2014.00107.
40. Martinelli P, Sperduti M, Devauchelle AD, et al. Age-related changes in the functional network underlying specific and general autobiographical memory retrieval: a pivotal role for the anterior cingulate cortex. *PLoS One* 2013; 8: e82385. 20131218. DOI: 10.1371/journal.pone.0082385.
41. García-Cabezas M and Barbas H. Anterior Cingulate Pathways May Affect Emotions Through Orbitofrontal Cortex. *Cereb Cortex* 2017; 27: 4891-4910. DOI: 10.1093/cercor/bhw284.
42. Wang J, John Y and Barbas H. Pathways for Contextual Memory: The Primate Hippocampal Pathway to Anterior Cingulate Cortex. *Cereb Cortex* 2021; 31: 1807-1826. DOI: 10.1093/cercor/bhaa333.
43. Rolls ET. The cingulate cortex and limbic systems for emotion, action, and memory. *Brain Struct Funct* 2019; 224: 3001-3018. 20190826. DOI: 10.1007/s00429-019-01945-2.
44. Kredlow MA, Fenster RJ, Laurent ES, et al. Prefrontal cortex, amygdala, and threat processing: implications for PTSD. *Neuropsychopharmacology* 2022; 47: 247-259. DOI: 10.1038/s41386-021-01155-7.
45. Thomaes K, Dorrepaal E, Draijer N, et al. Increased anterior cingulate cortex and hippocampus activation in Complex PTSD during encoding of negative words. *Soc Cogn Affect Neurosci* 2013; 8: 190-200. 20111207. DOI: 10.1093/scan/nsr084.
46. van der Kolk B. Posttraumatic stress disorder and the nature of trauma. *Dialogues in Clinical Neuroscience* 2000; 2: 7-22. DOI: 10.31887/DCNS.2000.2.1/bvdolk.
47. Kensinger EA, Addis DR and Atapattu RK. Amygdala activity at encoding corresponds with memory vividness and with memory for select episodic details. *Neuropsychologia* 2011; 49: 663-673. 20110122. DOI: 10.1016/j.neuropsychologia.2011.01.017.
48. Murty VP, Ritchey M, Adcock RA, et al. fMRI studies of successful emotional memory encoding: A quantitative meta-analysis. *Neuropsychologia* 2010; 48: 3459-3469. 20100803. DOI: 10.1016/j.neuropsychologia.2010.07.030.
49. Šimić G, Tkalčić M, Vukić V, et al. Understanding Emotions: Origins and Roles of the Amygdala. *Biomolecules* 2021; 11 20210531. DOI: 10.3390/biom11060823.
50. Liberzon I and Abelson JL. Context Processing and the Neurobiology of Post-Traumatic Stress Disorder. *Neuron* 2016; 92: 14-30. DOI: 10.1016/j.neuron.2016.09.039.
51. Fox AS, Oler JA, Tromp do PM, et al. Extending the amygdala in theories of threat processing. *Trends Neurosci* 2015; 38: 319-329. 20150404. DOI: 10.1016/j.tins.2015.03.002.
52. Etkin A, Egner T and Kalisch R. Emotional processing in anterior cingulate and medial prefrontal cortex. *Trends Cogn Sci* 2011; 15: 85-93. 20101216. DOI: 10.1016/j.tics.2010.11.004.
53. Pitts BL, Eisenberg ML, Bailey HR, et al. PTSD is associated with impaired event processing and memory for everyday events. *Cognitive Research: Principles and Implications* 2022; 7: 35. DOI: 10.1186/s41235-022-00386-6.
54. Sharot T, Riccardi AM, Raio CM, et al. Neural mechanisms mediating optimism bias. *Nature* 2007; 450: 102-105. 20071024. DOI: 10.1038/nature06280.
55. Wagner G, Koch K, Schachtzabel C, et al. Self-referential processing influences functional activation during cognitive control: an fMRI study. *Soc Cogn Affect Neurosci* 2013; 8: 828-837. 20120713. DOI: 10.1093/scan/nss074.
56. Lanius RA, Bluhm RL and Frewen PA. How understanding the neurobiology of complex post-traumatic stress disorder can inform clinical practice: a social cognitive and affective neuroscience approach. *Acta Psychiatrica Scandinavica* 2011; 124: 331-348. DOI: <https://doi.org/10.1111/j.1600-0447.2011.01755.x>.
57. van der Kolk BA. Clinical Implications of Neuroscience Research in PTSD. *Annals of the New York Academy of Sciences* 2006; 1071: 277-293. DOI: <https://doi.org/10.1196/annals.1364.022>.
58. Barber M, Evans S, Marks R, et al. "I am not pain, I have pain": A pilot study examining iRest yoga nidra as a mind-body intervention for persistent pain. *Complementary Therapies in Clinical Practice* 2025; 59: 101955.

59. Mueser KT, Gottlieb JD, Xie H, et al. Evaluation of cognitive restructuring for post-traumatic stress disorder in people with severe mental illness. *Br J Psychiatry* 2015; 206: 501-508. 20150409. DOI: 10.1192/bjp.bp.114.147926.
60. Fisher J. Trauma-informed stabilisation treatment: A new approach to treating unsafe behaviour. *Australian Clinical Psychologist* 2017; 3: 1744.
61. Zhang X, Hack LM, Bertrand C, et al. Negative Affect Circuit Subtypes and Neural, Behavioral, and Affective Responses to MDMA: A Randomized Clinical Trial. *JAMA Network Open* 2025; 8: e257803-e257803. DOI: 10.1001/jamanetworkopen.2025.7803.
62. Young DA, Chao L, Neylan TC, et al. Association among anterior cingulate cortex volume, psychophysiological response, and PTSD diagnosis in a Veteran sample. *Neurobiol Learn Mem* 2018; 155: 189-196. 20180804. DOI: 10.1016/j.nlm.2018.08.006.
63. Carhart-Harris RL, Murphy K, Leech R, et al. The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity. *Biol Psychiatry* 2015; 78: 554-562. 20140110. DOI: 10.1016/j.biopsych.2013.12.015.
64. Sottile RJ and Vida T. A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy. *Front Psychiatry* 2022; 13: 991753. 20221012. DOI: 10.3389/fpsy.2022.991753.
65. Doss MK, Weafer J, Gallo DA, et al. MDMA Impairs Both the Encoding and Retrieval of Emotional Recollections. *Neuropsychopharmacology* 2018; 43: 791-800. 2017/08/22. DOI: 10.1038/npp.2017.171.
66. Luoma J and Lear MK. MDMA-Assisted Therapy as a Means to Alter Affective, Cognitive, Behavioral, and Neurological Systems Underlying Social Dysfunction in Social Anxiety Disorder. *Front Psychiatry* 2021; 12: 733893. 20210927. DOI: 10.3389/fpsy.2021.733893.
67. Bedi G, Phan KL, Angstadt M, et al. Effects of MDMA on sociability and neural response to social threat and social reward. *Psychopharmacology (Berl)* 2009; 207: 73-83. 20090813. DOI: 10.1007/s00213-009-1635-z.
68. Gattuso JJ, Perkins D, Ruffell S, et al. Default Mode Network Modulation by Psychedelics: A Systematic Review. *Int J Neuropsychopharmacol* 2023; 26: 155-188. DOI: 10.1093/ijnp/pyac074.
69. Schmid Y and Bershad AK. Altered States and Social Bonds: Effects of MDMA and Serotonergic Psychedelics on Social Behavior as a Mechanism Underlying Substance-Assisted Therapy. *Biol Psychiatry Cogn Neurosci Neuroimaging* 2024; 9: 490-499. 20240209. DOI: 10.1016/j.bpsc.2024.02.001.
70. van der Kolk BA, Wang JB, Yehuda R, et al. Effects of MDMA-assisted therapy for PTSD on self-experience. *PLoS One* 2024; 19: e0295926. 20240110. DOI: 10.1371/journal.pone.0295926.
71. Sar V. Developmental trauma, complex PTSD, and the current proposal of DSM-5. *Eur J Psychotraumatol* 2011; 2 20110307. DOI: 10.3402/ejpt.v2i0.5622.
72. Akiki TJ, Averill CL and Abdallah CG. A Network-Based Neurobiological Model of PTSD: Evidence From Structural and Functional Neuroimaging Studies. *Curr Psychiatry Rep* 2017; 19: 81. 20170919. DOI: 10.1007/s11920-017-0840-4.
73. Thomason ME and Marusak HA. Toward understanding the impact of trauma on the early developing human brain. *Neuroscience* 2017; 342: 55-67. 20160215. DOI: 10.1016/j.neuroscience.2016.02.022.
74. Edmondson D. An Enduring Somatic Threat Model of Posttraumatic Stress Disorder Due to Acute Life-Threatening Medical Events. *Soc Personal Psychol Compass* 2014; 8: 118-134. DOI: 10.1111/spc3.12089.
75. Birkeland MS, Skar AS and Jensen TK. Understanding the relationships between trauma type and individual posttraumatic stress symptoms: a cross-sectional study of a clinical sample of children and adolescents. *J Child Psychol Psychiatry* 2022; 63: 1496-1504. 20220318. DOI: 10.1111/jcpp.13602.
76. Kiser LJ, Nurse W, Lucksted A, et al. Understanding the Impact of Trauma on Family Life From the Viewpoint of Female Caregivers Living in Urban Poverty. *Traumatology (Tallahass Fla)* 2008; 14: 77-90. DOI: 10.1177/1534765608320329.
77. Baroncelli CMC, Lodder P, van der Lee M, et al. The role of enmeshment and undeveloped self, subjugation and self-sacrifice in childhood trauma and attachment related problems: The relationship with self-concept clarity. *Acta Psychologica* 2025; 254: 104839. DOI: <https://doi.org/10.1016/j.actpsy.2025.104839>.

78. Schott GD. Pictures of pain: their contribution to the neuroscience of empathy. *Brain* 2015; 138: 812-820. 20150121. DOI: 10.1093/brain/awu395.
79. Ford JD and Courtois CA. Complex PTSD and borderline personality disorder. *Borderline Personality Disorder and Emotion Dysregulation* 2021; 8: 16. DOI: 10.1186/s40479-021-00155-9.
80. Dumont GJ, Sweep FC, van der Steen R, et al. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. *Soc Neurosci* 2009; 4: 359-366. DOI: 10.1080/17470910802649470.
81. Borissova A, Ferguson B, Wall MB, et al. Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment. *Journal of Psychopharmacology* 2021; 35: 547-555. DOI: 10.1177/0269881120926673.
82. Albert AE and Back AL. Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach. *Front Psychiatry* 2025; 16: 1529427. 20250402. DOI: 10.3389/fpsy.2025.1529427.
83. Yadav G, McNamara S and Gunturu S. Trauma-Informed Therapy. *StatPearls*. Treasure Island (FL), 2025.
84. Yehuda R. Understanding Heterogeneous Effects of Trauma Exposure: Relevance to Postmortem Studies of PTSD. *Psychiatry* 2004; 67: 391-397. DOI: 10.1521/psyc.67.4.391.56572.
85. Green B. Prazosin in the treatment of PTSD. *J Psychiatr Pract* 2014; 20: 253-259. DOI: 10.1097/01.pra.0000452561.98286.1e.
86. Nirmalani-Gandhy A, Sanchez D and Catalano G. Terazosin for the treatment of trauma-related nightmares: a report of 4 cases. *Clin Neuropharmacol* 2015; 38: 109-111. DOI: 10.1097/wnf.000000000000077.
87. Smith C and Koola MM. Evidence for Using Doxazosin in the Treatment of Posttraumatic Stress Disorder. *Psychiatr Ann* 2016; 46: 553-555. 20160912. DOI: 10.3928/00485713-20160728-01.
88. Taylor F and Raskind MA. The alpha1-adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma posttraumatic stress disorder. *J Clin Psychopharmacol* 2002; 22: 82-85. DOI: 10.1097/00004714-200202000-00013.
89. Arnsten AFT, Raskind MA, Taylor FB, et al. The effects of stress exposure on prefrontal cortex: Translating basic research into successful treatments for post-traumatic stress disorder. *Neurobiology of Stress* 2015; 1: 89-99. DOI: <https://doi.org/10.1016/j.ynstr.2014.10.002>.
90. Vaslavski A, Gross AH, Israel S, et al. The effect of MDMA administration on oxytocin concentration levels: systematic review and a multilevel meta-analysis in humans. *Neuroscience & Biobehavioral Reviews* 2025; 177: 106324. DOI: <https://doi.org/10.1016/j.neubiorev.2025.106324>.
91. Burek GA, Waite MR, Heslin K, et al. Low-dose clonidine in veterans with Posttraumatic stress disorder. *Journal of Psychiatric Research* 2021; 137: 480-485. DOI: <https://doi.org/10.1016/j.jpsychires.2021.03.008>.
92. Cheung LK. Guanfacine as an Adjunct Treatment for Complex Post-Traumatic Stress Disorder: A Case Report. *J Korean Acad Child Adolesc Psychiatry* 2025; 36: 78-82. DOI: 10.5765/jkacap.240037.
93. Yu Y, Li Y, Han D, et al. Effect of Dexmedetomidine on Posttraumatic Stress Disorder in Patients Undergoing Emergency Trauma Surgery: A Randomized Clinical Trial. *JAMA Network Open* 2023; 6: e2318611-e2318611. DOI: 10.1001/jamanetworkopen.2023.18611.
94. Arluk S, Matar MA, Carmi L, et al. MDMA treatment paired with a trauma-cue promotes adaptive stress responses in a translational model of PTSD in rats. *Transl Psychiatry* 2022; 12: 181. 20220503. DOI: 10.1038/s41398-022-01952-8.
95. Belkin MR and Schwartz TL. Alpha-2 receptor agonists for the treatment of posttraumatic stress disorder. *Drugs Context* 2015; 4: 212286. 20150814. DOI: 10.7573/dic.212286.
96. Recchia A, Tonti MP, Mirabella L, et al. The Pharmacological Class Alpha 2 Agonists for Stress Control in Patients with Respiratory Failure: The Main Actor in the Different Acts. *Stresses* 2023; 3: 1-10.
97. Bexis S and Docherty JR. Role of alpha2A-adrenoceptors in the effects of MDMA on body temperature in the mouse. *Br J Pharmacol* 2005; 146: 1-6. DOI: 10.1038/sj.bjp.0706320.
98. Sessa B, Higbed L and Nutt D. A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy. *Front Psychiatry* 2019; 10: 138. 2019/04/06. DOI: 10.3389/fpsy.2019.00138.
99. Carhart-Harris RL, Wall MB, Erritzoe D, et al. The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. *Int J Neuropsychopharmacol* 2014; 17: 527-540. 2013/12/19. DOI: 10.1017/S1461145713001405.

100. Mahoney D and Markel B. An Integrative Approach to Conceptualizing and Treating Complex Trauma. *Psychoanalytic Social Work* 2016; 23: 1-22. DOI: 10.1080/15228878.2015.1104640.
101. Busso DS, McLaughlin KA and Sheridan MA. Media exposure and sympathetic nervous system reactivity predict PTSD symptoms after the Boston marathon bombings. *Depress Anxiety* 2014; 31: 551-558. DOI: 10.1002/da.22282.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.